Mark Beards is a seasoned professional with over 30 years of experience in the life sciences and financial sectors, focusing on operational and Board roles across the value chain in life sciences.

Specializing in translating ideas into successful business ventures, Mark has a strong track record of raising approximately $40M in seed and Series A funding for multiple companies.

His areas of expertise encompass executive leadership, fund raising, commercialization, R&D, licensing and business development, as well as corporate strategy.

Mark has a diverse background that includes engagements with global Pharma companies and development-stage biotechs, spanning various therapy areas such as rare diseases, anti-infectives, autoimmune diseases, cardiovascular, oncology, respiratory, and more.

His educational qualifications include regulatory exams at 7City, a Master of Arts (M.A.) in Mathematics from Oxford University, ACMA in Accounting from The Chartered Institute of Management Accountants, a Diploma of Business Management from Henley Management College, and a Bachelor of Arts (B.A.) in Mathematics from Oxford University.

Mark Beards has held key positions in several prestigious organizations, including Managing Director, Biotechnology at MotionHall, Senior Board Advisor at UTILITY therapeutics, Chief Executive Officer at Sutura Therapeutics, Owner at Fountainhead Consulting, and roles at Celixir, CELL THERAPY LIMITED, KPMG, Charles River Associates, Goldman Sachs, McKinsey & Company, GlaxoSmithKline, and Abbott Laboratories.